BioNTech has initiated a Phase III clinical trial for its oncology candidate BNT324 in metastatic castration-resistant prostate cancer, aiming to compare the drug against current standard chemotherapy ...

BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board as Chief People Officer (“CPO”) effective March 1 ...

BioNTech SE (Nasdaq: BNTX, "BioNTech" or "the Company") announced today that the Supervisory Board has appointed Kylie Jimenez to the Management Board ...

BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Fintel reports that on January 16, 2026, Goldman Sachs upgraded their outlook for BioNTech SE - Depositary Receipt ...

With 2026 set to be a banner year for M&A as buyers facing patent cliffs compete for a limited pool of late-stage assets ( [3]) , companies demonstrating disciplined pivotal execution and FDA ...

They could perhaps see sustained runs beyond this year.

German biotech BioNTech today announced that the US Food and Drug Administration (FDA) has granted fast track designation to ...

Yeast-based protein expression systems will likely play an important role in vaccine production during future pandemics.

Today, Benzinga's options scanner spotted 20 options trades for BioNTech. This is not a typical pattern. The sentiment among these major traders is split, with 55% bullish and 20% bearish. Among all ...

BioNTech SE is flexible about its future structure as it prepares to bring a slew of cancer drugs to market, with its chief executive officer saying he would consider a deal with a partner that gets ...